Alnylam Pharmaceuticals, Inc.
ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products includeā¦ read more
Healthcare
Biotechnology
22 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$205.52
Price+0.02%
$0.04
1Y
Price
Market Cap
$27.440b
Large
Price/Earnings 3y Avg5y Avg
37x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+26.1%
EBITDA Margin+17.7%
Net Profit Margin+4.2%
Free Cash Flow Margin+26.1%
EBITDA Margin+17.7%
Net Profit Margin+4.2%
Free Cash Flow MarginRevenue
$4.804b
+15.4%
1y CAGR+34.5%
3y CAGR+45.0%
5y CAGREarnings
$807.988m
+84.0%
1y CAGR+111.2%
3y CAGR+98.7%
5y CAGREPS
$5.92
+80.7%
1y CAGR+108.6%
3y CAGR+97.0%
5y CAGRBook Value
$1.354b
$5.559b
Assets$4.205b
Liabilities$1.267b
DebtDebt to Assets
22.8%
1.4x
Debt to EBITDAFree Cash Flow
$542.543m
+37.8%
1y CAGR+343.0%
3y CAGR+284.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company